{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:59:55Z","timestamp":1785769195040,"version":"3.56.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MedScience"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11684-026-1201-7","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T03:08:41Z","timestamp":1775012921000},"page":"329-344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting circSFPQ_008\/SFPQ\/BRCA1 axis for overcoming platinum resistance in ovarian cancer"],"prefix":"10.1007","volume":"20","author":[{"given":"Yinan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baixue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renci","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujie","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"1","key":"1201_CR1","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70(1): 7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"1201_CR2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/ijc.34002","volume":"151","author":"CJ Cabasag","year":"2022","unstructured":"Cabasag CJ, Fagan PJ, Ferlay J, Vignat J, Laversanne M, Liu L, van der Aa MA, Bray F, Soerjomataram I. Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer 2022; 151(9): 1535\u20131541","journal-title":"Int J Cancer"},{"issue":"9951","key":"1201_CR3","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014; 384(9951): 1376\u20131388","journal-title":"Lancet"},{"issue":"4","key":"1201_CR4","first-page":"284","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018; 68(4): 284\u2013296","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1201_CR5","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin 2019; 69(4): 280\u2013304","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"1201_CR6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med 2019; 381(20): 1929\u20131939","journal-title":"N Engl J Med"},{"issue":"1","key":"1201_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexcr.2014.12.001","volume":"336","author":"S Busschots","year":"2015","unstructured":"Busschots S, O\u2019Toole S, O\u2019Leary JJ, Stordal B. Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. Exp Cell Res 2015; 336(1): 1\u201314","journal-title":"Exp Cell Res"},{"issue":"5","key":"1201_CR8","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3390\/cells9051299","volume":"9","author":"M Nowak","year":"2020","unstructured":"Nowak M, Klink M. The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer. Cells 2020; 9(5): 1299","journal-title":"Cells"},{"issue":"1","key":"1201_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11684-014-0305-7","volume":"8","author":"Y Fu","year":"2014","unstructured":"Fu Y, Wang X, Pan Z, Xie X. Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: a retrospective study of 251 cases. Front Med 2014; 8(1): 91\u201395","journal-title":"Front Med"},{"issue":"4","key":"1201_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3892\/or.2022.8293","volume":"47","author":"L Yang","year":"2022","unstructured":"Yang L, Xie HJ, Li YY, Wang X, Liu XX, Mai J. Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer. Oncol Rep 2022; 47(4): 82","journal-title":"Oncol Rep"},{"issue":"1","key":"1201_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","volume":"7","author":"JS Brown","year":"2017","unstructured":"Brown JS, O\u2019Carrigan B, Jackson SP, Yap TA. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov 2017; 7(1): 20\u201337","journal-title":"Cancer Discov"},{"key":"1201_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","volume":"60","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer 2016; 60: 49\u201358","journal-title":"Eur J Cancer"},{"issue":"8","key":"1201_CR13","doi-asserted-by":"publisher","first-page":"viii13","DOI":"10.1093\/annonc\/mdx446","volume":"28","author":"E Christie","year":"2017","unstructured":"Christie El, Bowtell Ddl. Acquired chemotherapy resistance in ovarian cancer. Ann Oncol 2017; 28(8): viii13\u2013viii15","journal-title":"Ann Oncol"},{"issue":"8","key":"1201_CR14","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","volume":"27","author":"M Moschetta","year":"2016","unstructured":"Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol 2016; 27(8): 1449\u20131455","journal-title":"Ann Oncol"},{"issue":"2","key":"1201_CR15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nm.4032","volume":"22","author":"Y Du","year":"2016","unstructured":"Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR4th, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med 2016; 22(2): 194\u2013201","journal-title":"Nat Med"},{"issue":"9","key":"1201_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1158\/2159-8290.CD-17-0734","volume":"7","author":"SM Domchek","year":"2017","unstructured":"Domchek SM. Reversion mutations with clinical use of PARP inhibitors: many genes, many versions. Cancer Discov 2017; 7(9): 937\u2013939","journal-title":"Cancer Discov"},{"issue":"2","key":"1201_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","volume":"9","author":"KK Lin","year":"2019","unstructured":"Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O\u2019Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov 2019; 9(2): 210\u2013219","journal-title":"Cancer Discov"},{"issue":"22","key":"1201_CR18","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","volume":"29","author":"B Norquist","year":"2011","unstructured":"Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM. Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011; 29(22): 3008\u20133015","journal-title":"J Clin Oncol"},{"issue":"7","key":"1201_CR19","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","volume":"21","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, Lee EK, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, F\u00e4rkkil\u00e4 A, Chowdhury D, Curtis J, Quinn RS, Bowes B, D\u2019Andrea AD, Shapiro GI, Matulonis UA. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020; 21(7): 957\u2013968","journal-title":"Lancet Oncol"},{"issue":"21","key":"1201_CR20","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30(21): 2654\u20132663","journal-title":"J Clin Oncol"},{"issue":"7","key":"1201_CR21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm.2377","volume":"17","author":"N Johnson","year":"2011","unstructured":"Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D\u2019Andrea AD, Curtin NJ, Wong KK, Shapiro GI. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011; 17(7): 875\u2013882","journal-title":"Nat Med"},{"issue":"12","key":"1201_CR22","doi-asserted-by":"publisher","first-page":"108184","DOI":"10.1016\/j.celrep.2020.108184","volume":"32","author":"K Klotz-Noack","year":"2020","unstructured":"Klotz-Noack K, Klinger B, Rivera M, Bublitz N, Uhlitz F, Riemer P, L\u00fcthen M, Sell T, Kasack K, Gastl B, Ispasanie SSS, Simon T, Janssen N, Schwab M, Zuber J, Horst D, Bl\u00fcthgen N, Sch\u00e4fer R, Morkel M, Sers C. SFPQ depletion is synthetically lethal with BRAFV600E in colorectal cancer cells. Cell Rep 2020; 32(12): 108184","journal-title":"Cell Rep"},{"issue":"10","key":"1201_CR23","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00018-019-03033-4","volume":"76","author":"HC de Silva","year":"2019","unstructured":"de Silva HC, Lin MZ, Phillips L, Martin JL, Baxter RC. IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer. Cell Mol Life Sci 2019; 76(10): 2015\u20132030","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1201_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/nar\/gkq738","volume":"39","author":"C Rajesh","year":"2011","unstructured":"Rajesh C, Baker DK, Pierce AJ, Pittman DL. The splicing-factor related protein SFPQ\/PSF interacts with RAD51D and is necessary for homology-directed repair and sister chromatid cohesion. Nucleic Acids Res 2011; 39(1): 132\u2013145","journal-title":"Nucleic Acids Res"},{"issue":"19","key":"1201_CR25","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.3390\/ijms21197151","volume":"21","author":"YW Lim","year":"2020","unstructured":"Lim YW, James D, Huang J, Lee M. The emerging role of the RNA-binding protein SFPQ in neuronal function and neurodegeneration. Int J Mol Sci 2020; 21(19): 7151","journal-title":"Int J Mol Sci"},{"issue":"23","key":"1201_CR26","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.3390\/cancers13235993","volume":"13","author":"BG Matthews","year":"2021","unstructured":"Matthews BG, Bowden NA, Wong-Brown MW. Epigenetic mechanisms and therapeutic targets in chemoresistant high-grade serous ovarian cancer. Cancers (Basel) 2021; 13(23): 5993","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1201_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/genes11050556","volume":"11","author":"G Milazzo","year":"2020","unstructured":"Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, Giorgi FM. Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability. Genes (Basel) 2020; 11(5): 556","journal-title":"Genes (Basel)"},{"key":"1201_CR28","doi-asserted-by":"publisher","first-page":"104100","DOI":"10.1016\/j.ebiom.2022.104100","volume":"81","author":"S Ding","year":"2022","unstructured":"Ding S, Gao Y, Lv D, Tao Y, Liu S, Chen C, Huang Z, Zheng S, Hu Y, Chow LK, Wei Y, Feng P, Dai W, Wang X, Xia Y. DNTTIP1 promotes nasopharyngeal carcinoma metastasis via recruiting HDAC1 to DUSP2 promoter and activating ERK signaling pathway. EBioMedicine 2022; 81: 104100","journal-title":"EBioMedicine"},{"issue":"6","key":"1201_CR29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41419-020-2671-1","volume":"11","author":"JB Ma","year":"2020","unstructured":"Ma JB, Bai JY, Zhang HB, Jia J, Shi Q, Yang C, Wang X, He D, Guo P. KLF5 inhibits STAT3 activity and tumor metastasis in prostate cancer by suppressing IGF1 transcription cooperatively with HDAC1. Cell Death Dis 2020; 11(6): 466","journal-title":"Cell Death Dis"},{"issue":"12","key":"1201_CR30","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1182\/bloodadvances.2022007998","volume":"7","author":"TH Lai","year":"2023","unstructured":"Lai TH, Ozer HG, Gasparini P, Nigita G, Distefano R, Yu L, Ravikrishnan J, Yilmaz S, Gallegos J, Shukla S, Puduvalli V, Woyach J, Lapalombella R, Blachly J, Byrd JC, Sampath D. HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia. Blood Adv 2023; 7(12): 2897\u20132911","journal-title":"Blood Adv"},{"issue":"12","key":"1201_CR31","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cell.2022.04.021","volume":"185","author":"CX Liu","year":"2022","unstructured":"Liu CX, Chen LL. Circular RNAs: Characterization, cellular roles, and applications. Cell 2022; 185(12): 2016\u20132034","journal-title":"Cell"},{"issue":"2","key":"1201_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","volume":"22","author":"L Statello","year":"2021","unstructured":"Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol 2021; 22(2): 96\u2013118","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"1201_CR33","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/s11684-023-1004-z","volume":"17","author":"P Zhao","year":"2023","unstructured":"Zhao P, Wang Y, Yu X, Nan Y, Liu S, Li B, Cui Z, Liu Z. Long noncoding RNA LOC646029 functions as a ceRNA to suppress ovarian cancer progression through the miR-627-3p\/SPRED1 axis. Front Med 2023; 17(5): 924\u2013938","journal-title":"Front Med"},{"issue":"9","key":"1201_CR34","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1016\/j.ymthe.2021.08.002","volume":"29","author":"J Ma","year":"2021","unstructured":"Ma J, Du WW, Zeng K, Wu N, Fang L, Lyu J, Yee AJ, Yang BB. An antisense circular RNA circSCRIB enhances cancer progression by suppressing parental gene splicing and translation. Mol Ther 2021; 29(9): 2754\u20132768","journal-title":"Mol Ther"},{"issue":"3","key":"1201_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nsmb.2959","volume":"22","author":"Z Li","year":"2015","unstructured":"Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, Zhong G, Yu B, Hu W, Dai L, Zhu P, Chang Z, Wu Q, Zhao Y, Jia Y, Xu P, Liu H, Shan G. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol 2015; 22(3): 256\u2013264","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"1201_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.devcel.2023.11.020","volume":"59","author":"M Xiao","year":"2024","unstructured":"Xiao M, Wang F, Chen N, Zhang H, Cao J, Yu Y, Zhao B, Ji J, Xu P, Li L, Shen L, Lin X, Feng XH. Smad4 sequestered in SFPQ condensates prevents TGF-\u03b2 tumor-suppressive signaling. Dev Cell 2024; 59(1): 48\u201363.e8","journal-title":"Dev Cell"},{"issue":"13","key":"1201_CR37","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.7150\/jca.25427","volume":"9","author":"Y Tao","year":"2018","unstructured":"Tao Y, Ma C, Fan Q, Wang Y, Han T, Sun C. MicroRNA-1296 facilitates proliferation, migration and invasion of colorectal cancer cells by targeting SFPQ. J Cancer 2018; 9(13): 2317\u20132326","journal-title":"J Cancer"},{"issue":"22","key":"1201_CR38","doi-asserted-by":"publisher","first-page":"7456","DOI":"10.1093\/nar\/gkm735","volume":"35","author":"S Beneke","year":"2007","unstructured":"Beneke S, B\u00fcrkle A. Poly(ADP-ribosyl)ation in mammalian ageing. Nucleic Acids Res 2007; 35(22): 7456\u20137465","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1201_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrc.2015.4","volume":"16","author":"PA Jeggo","year":"2016","unstructured":"Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer 2016; 16(1): 35\u201342","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"1201_CR40","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.ctrv.2014.10.003","volume":"40","author":"S O\u2019Grady","year":"2014","unstructured":"O\u2019Grady S, Finn SP, Cuffe S, Richard DJ, O\u2019Byrne KJ, Barr MP. The role of DNA repair pathways in cisplatin resistant lung cancer. Cancer Treat Rev 2014; 40(10): 1161\u20131170","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1201_CR41","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2\/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021; 22(5): 620\u2013631","journal-title":"Lancet Oncol"},{"issue":"1","key":"1201_CR42","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-med-050913-022545","volume":"66","author":"CJ Lord","year":"2015","unstructured":"Lord CJ, Tutt AN, Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med 2015; 66(1): 455\u2013470","journal-title":"Annu Rev Med"},{"issue":"6","key":"1201_CR43","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s11684-024-1083-5","volume":"18","author":"J Li","year":"2024","unstructured":"Li J, Chen Y, He M, Chen X, Wen H, Kang Y, Liu K, Lou G, Wang X, Wen Q, Wang L, Lin Z. First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive\/BRCA wild-type ovarian cancer: real-world multicenter study. Front Med 2024; 18(6): 1026\u20131034","journal-title":"Front Med"},{"issue":"21","key":"1201_CR44","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","volume":"23","author":"B Weigelt","year":"2017","unstructured":"Weigelt B, Comino-M\u00e9ndez I, de Bruijn I, Tian L, Meisel JL, Garc\u00eda-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin Cancer Res 2017; 23(21): 6708\u20136720","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1201_CR45","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1200\/JCO.2016.70.4627","volume":"35","author":"EL Christie","year":"2017","unstructured":"Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL. Reversion of BRCA1\/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol 2017; 35(12): 1274\u20131280","journal-title":"J Clin Oncol"},{"issue":"3","key":"1201_CR46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41571-021-00585-y","volume":"19","author":"LS Kristensen","year":"2022","unstructured":"Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol 2022; 19(3): 188\u2013206","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1201_CR47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12943-020-01286-3","volume":"19","author":"W Zhou","year":"2020","unstructured":"Zhou W, Cai Z, Liu J, Wang DS, Ju HQ, Xu RH. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer 2020; 19(1): 172","journal-title":"Mol Cancer"},{"issue":"8","key":"1201_CR48","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.7150\/thno.42174","volume":"10","author":"A Huang","year":"2020","unstructured":"Huang A, Zheng H, Wu Z, Chen M, Huang Y. Circular RNA-protein interactions: functions, mechanisms, and identification. Theranostics 2020; 10(8): 3503\u20133517","journal-title":"Theranostics"},{"issue":"7995","key":"1201_CR49","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-023-06834-7","volume":"625","author":"D Huang","year":"2024","unstructured":"Huang D, Zhu X, Ye S, Zhang J, Liao J, Zhang N, Zeng X, Wang J, Yang B, Zhang Y, Lao L, Chen J, Xin M, Nie Y, Saw PE, Su S, Song E. Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides. Nature 2024; 625(7995): 593\u2013602","journal-title":"Nature"},{"issue":"11","key":"1201_CR50","first-page":"1393","volume":"5","author":"K Ding","year":"2024","unstructured":"Ding K, Liu H, Yang H, Zhu H, Ma J, Peng H, Huang H, Shi W, Cao L, Wu W, Zhao X, Shi X, Li J, Zhang X, Fan L. A prospective phase 2 study of combination epigenetic therapy against relapsed\/refractory peripheral T cell lymphoma. Med (N Y) 2024; 5(11): 1393\u20131401.e2","journal-title":"Med (N Y)"},{"issue":"2","key":"1201_CR51","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ygyno.2012.02.019","volume":"125","author":"DS Dizon","year":"2012","unstructured":"Dizon DS, Blessing JA, Penson RT, Drake RD, Walker JL, Johnston CM, Disilvestro PA, Fader AN. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012; 125(2): 367\u2013371","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1201_CR52","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13046-025-03335-5","volume":"44","author":"X Xu","year":"2025","unstructured":"Xu X, Wang Q, Guo K, Xu J, Lu Y, Chen H, Hu W, Fu Y, Sun L, He Y, Chen Z, Xia W, Pan M, Lin B, Yang W, Wang Q, Wen Z, Cao Q, Xiao P. CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages. J Exp Clin Cancer Res 2025; 44(1): 67","journal-title":"J Exp Clin Cancer Res"},{"issue":"40","key":"1201_CR53","doi-asserted-by":"publisher","first-page":"36044","DOI":"10.1021\/jacs.5c08929","volume":"147","author":"WA Pytel","year":"2025","unstructured":"Pytel WA, Patel U, Smalley JP, Millard CJ, Brown EA, Pavan AR, Wang S, Kalin JH, Dos Santos JL, Cole PA, Hodgkinson JT, Schwabe JWR. The allosteric regulator inositol phosphate dramatically affects the efficacy and selectivity of inhibitors for different HDAC complexes. J Am Chem Soc 2025; 147(40): 36044\u201336052","journal-title":"J Am Chem Soc"},{"issue":"22","key":"1201_CR54","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1038\/s41388-020-1292-6","volume":"39","author":"I Pellarin","year":"2020","unstructured":"Pellarin I, Dall\u2019Acqua A, Gambelli A, Pellizzari I, D\u2019Andrea S, Sonego M, Lorenzon I, Schiappacassi M, Belletti B, Baldassarre G. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity. Oncogene 2020; 39(22): 4390\u20134403","journal-title":"Oncogene"}],"container-title":["MedScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-026-1201-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11684-026-1201-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-026-1201-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:04:04Z","timestamp":1785765844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11684-026-1201-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1201"],"URL":"https:\/\/doi.org\/10.1007\/s11684-026-1201-7","relation":{},"ISSN":["3091-4973","3091-4981"],"issn-type":[{"value":"3091-4973","type":"print"},{"value":"3091-4981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflicts of interest\n                      Yinan Jiang, Dongmei Zhou, Yan Liu, Baixue Li, Renci Liu, Jianqi Li, and Xiujie Sheng declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This study was approved by the Ethics Committee of the Third Affiliated Hospital of Guangzhou Medical University Institutional Review Board. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consents were obtained from all patients for being included in the study. All institutional and national guidelines for the care and use of laboratory animals were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}